Also known as Section 174A, R&E capitalization, R&D amortization
Section 174 governs how R&D costs are deducted.
Key takeaways
Section 174 governs how R&D costs are deducted. From 2022-2024 companies had to capitalize and amortize them (5 years domestic, 15 foreign), inflating taxable income. The One Big Beautiful Bill Act restored immediate deduction of domestic R&D via new Section 174A for tax years beginning after 2024; foreign R&D still amortizes over 15 years.
A startup spent $1,000,000 on domestic R&D in 2023. Under the old rules it could deduct only about $100,000 that year (half of a 5-year straight-line amount), creating phantom taxable income on a cash-losing company. For 2025, under Section 174A, the full $1,000,000 is deductible immediately, and as a small business it can amend 2022-2024 to recover the earlier over-taxation.
For tax years beginning after Dec 31, 2024, domestic R&E costs are immediately deductible under IRC Sec. 174A. Foreign R&E must still be capitalized and amortized over 15 years. Small taxpayers (under the Sec. 448(c) gross-receipts threshold, $31M for 2025) may amend 2022-2024 returns.
Source: IRC Sec. 174 & 174A; One Big Beautiful Bill Act (enacted July 2025) (2026)
The 2022-2024 capitalization rule quietly created tax bills for unprofitable startups by forcing them to spread R&D deductions over years, so a company burning cash could still owe income tax on 'profit' it never made. Section 174A's restoration of immediate domestic expensing removes that trap, and small startups can reclaim taxes overpaid in 2022-2024.